Mariner, LLC Ironwood Pharmaceuticals Inc Transaction History

Mariner, LLC

$55.8 Billion
Q3 2024

A detailed history of Mariner, LLC transactions in Ironwood Pharmaceuticals Inc stock. As of the latest transaction made, Mariner, LLC holds 45,213 shares of IRWD stock, worth $201,197. This represents 0.0% of its overall portfolio holdings.

Number of Shares

45,213

Previous 80,429 43.79%

Holding current value

$201,197

Previous $524,000 64.69%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$3.93 - $7.04 $138,398 - $247,920	-35,216 Reduced 43.79%	45,213 $185,000
Q2 2024 Aug 13, 2024	BUY	$5.58 - $8.61 $64,945 - $100,211	11,639 Added 16.92%	80,429 $524,000
Q1 2024 May 15, 2024	BUY	$8.32 - $15.45 $348,225 - $646,644	41,854 Added 155.38%	68,790 $599,000
Q4 2023 Feb 14, 2024	BUY	$8.79 - $11.51 $23,574 - $30,869	2,682 Added 11.06%	26,936 $308,000
Q3 2023 Nov 13, 2023	SELL	$8.25 - $11.35 $46,670 - $64,206	-5,657 Reduced 18.91%	24,254 $233,000
Q2 2023 Aug 11, 2023	BUY	$10.1 - $11.6 $63,013 - $72,372	6,239 Added 26.36%	29,911 $318,000
Q1 2023 May 12, 2023	SELL	$10.37 - $12.56 $9,135 - $11,065	-881 Reduced 3.59%	23,672 $249,000
Q4 2022 Feb 14, 2023	SELL	$9.9 - $12.43 $14,691 - $18,446	-1,484 Reduced 5.7%	24,553 $304,000
Q3 2022 Nov 10, 2022	BUY	$10.14 - $12.38 $15,037 - $18,359	1,483 Added 6.04%	26,037 $270,000
Q2 2022 Aug 15, 2022	BUY	$11.05 - $12.72 $14,818 - $17,057	1,341 Added 5.78%	24,554 $283,000
Q1 2022 May 13, 2022	BUY	$10.61 - $12.88 $246,289 - $298,983	23,213 New	23,213 $292,000

Others Institutions Holding IRWD

# of Institutions

237

Shares Held

162M

Call Options Held

11.2M

Put Options Held

9.1K

View Full List

About IRONWOOD PHARMACEUTICALS INC

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $682M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

More about IRWD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.

Account